This finding reaffirms the conclusion that the combination of the WASL, GRB2, SRC, and Tks4 genes exhibits a colon cancer-specific expression profile, suggesting their suitability for use as a combined colon cancer biomarker. This evidence concerns the gene SH3PXD2B and malignant colon neoplasm.